deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03158727

Cx611-0204 SEPCELL Study (SEPCELL)

A Phase Ib/IIa, Randomised, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess the Safety and Efficacy of Expanded Cx611 Allogeneic Adipose-derived Stem Cells (eASCs) for the Intravenous Treatment of Adult Patients With Severe Community-acquired Bacterial Pneumonia and Admitted to the Intensive Care Unit

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Conditions Bacterial Pneumonia
Interventions Cx611 Placebo
Updated 12 times since 2017 Last updated: Feb 1, 2022 Started: Jan 30, 2017 Primary completion: Jul 7, 2020 Completion: Jul 7, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Bacterial Pneumonia and is currently completed. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshotRecruiting~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshotRecruiting~Apr 2019 – ~May 2019 · 30 days · monthly snapshotRecruiting~May 2019 – ~May 2020 · 12 months · monthly snapshotRecruiting~May 2020 – ~Jul 2020 · 2 months · monthly snapshotActive Not Recruiting~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshotActive Not Recruiting~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~May 2022 · 16 months · monthly snapshotActive Not Recruiting~May 2022 – ~Jul 2024 · 26 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. May 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Jan 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 7 earlier versions

  1. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. May 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  4. May 2019 — May 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jan 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • Centre Hospital Regional Universitaire de Limoges
  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain
  • European Commission
  • Hospital San Carlos, Madrid
  • Tigenix S.A.U.
Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angoulême, France , Argenteuil, France , Barcelona, Spain , Brussels, Belgium , Clermont-Ferrand, France , Dijon, France , Getafe, Spain , Klaipėda, Lithuania , L'Hospitalet de Llobregat, Spain , La Roche-sur-Yon, France and 17 more locations